GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Voyageur Pharmaceuticals Ltd (TSXV:VM) » Definitions » EV-to-EBITDA

Voyageur Pharmaceuticals (TSXV:VM) EV-to-EBITDA : -4.96 (As of May. 23, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Voyageur Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Voyageur Pharmaceuticals's enterprise value is C$6.73 Mil. Voyageur Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Feb. 2024 was C$-1.36 Mil. Therefore, Voyageur Pharmaceuticals's EV-to-EBITDA for today is -4.96.

The historical rank and industry rank for Voyageur Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

TSXV:VM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -154.48   Med: 0   Max: 0
Current: -4.96

TSXV:VM's EV-to-EBITDA is ranked worse than
100% of 714 companies
in the Drug Manufacturers industry
Industry Median: 14.535 vs TSXV:VM: -4.96

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-23), Voyageur Pharmaceuticals's stock price is C$0.05. Voyageur Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 was C$-0.008. Therefore, Voyageur Pharmaceuticals's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Voyageur Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Voyageur Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyageur Pharmaceuticals EV-to-EBITDA Chart

Voyageur Pharmaceuticals Annual Data
Trend Dec14 Dec15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.60 -2.79 -4.11 -4.63 -3.84

Voyageur Pharmaceuticals Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.14 -4.62 -3.54 -3.84 -7.01

Competitive Comparison of Voyageur Pharmaceuticals's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Voyageur Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Voyageur Pharmaceuticals's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Voyageur Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Voyageur Pharmaceuticals's EV-to-EBITDA falls into.



Voyageur Pharmaceuticals EV-to-EBITDA Calculation

Voyageur Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=6.734/-1.357
=-4.96

Voyageur Pharmaceuticals's current Enterprise Value is C$6.73 Mil.
Voyageur Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Voyageur Pharmaceuticals  (TSXV:VM) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Voyageur Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.05/-0.008
=At Loss

Voyageur Pharmaceuticals's share price for today is C$0.05.
Voyageur Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.008.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Voyageur Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Voyageur Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Voyageur Pharmaceuticals (TSXV:VM) Business Description

Traded in Other Exchanges
Address
333 Southwest 7th Avenue, Suite 800, Calgary, AB, CAN, T2P 2Z1
Voyageur Pharmaceuticals Ltd is engaged in the development of pharmaceutical ingredients (API) minerals. The company focuses on developing barium and iodine radiocontrast products and bromine-based pharmaceutical products. It provides its products for medical applications and diagnostics.

Voyageur Pharmaceuticals (TSXV:VM) Headlines

No Headlines